Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

946 ARTÍCULOS , VIENDO DEL 376 AL 390

APOE4-driven lipid metabolic dysregulation in Alzheimer's disease: Multi-pathway mechanisms and therapeutic perspectives

Zhang WX, Yang YL, Yu JX, Jia LH, Huang HC.

Biochem Biophys Res Commun. 2025 Sep 8;778:152335. doi: 10.1016/j.bbrc.2025.152335. Epub 2025 Jul 10.

Neutral pH-Selective Inhibition of Cytosolic Cathepsin B: A Novel Drug Targeting Strategy for Traumatic Brain Injury and Alzheimer's Disease

Hook V, Podvin S, Yoon MC, Phan VV, Florio J, Spencer B, Mosier C, Cheng A, Ahuett S, Almaliti J, Gerwick WH, Rissman RA, O'Donoghue AJ.

ACS Chem Biol. 2025 Aug 15;20(8):1841-1848. doi: 10.1021/acschembio.5c00463. Epub 2025 Jul 23.

Autophagy and Cellular Senescence in Alzheimer's Disease: Key Drivers of Neurodegeneration

Hussain MS, Agrawal N, Ilma B, M M R, Nayak PP, Kaur M, Khachi A, Goyal K, Rekha A, Gupta S, Gupta G, Dua K.

CNS Neurosci Ther. 2025 Jul;31(7):e70503. doi: 10.1111/cns.70503.

Advances in mesenchymal stem cell and exosome-based therapies for aging and age-related diseases

Li H, Bai L.

Stem Cell Res Ther. 2025 Jul 26;16(1):401. doi: 10.1186/s13287-025-04318-1.

Mitochondrial Damage and Autophagy Dysregulation in Alzheimer's Disease: Mechanisms and Therapeutic Opportunities

Yu Q, Li L, Yu S, Han J, Cheng Q, Cui Z, Chen H, Li M, Lu Z.

Neurochem Res. 2025 Jul 28;50(4):251. doi: 10.1007/s11064-025-04490-z.

Dual Inhibitors of Acetylcholinesterase and Monoamine Oxidase-B for the Treatment of Alzheimer's Disease

Asim A, Jastrzębski MK, Kaczor AA.

Molecules. 2025 Jul 15;30(14):2975. doi: 10.3390/molecules30142975.

The potential of acupuncture in the treatment of Alzheimer's disease: An exploration from traditional Chinese medicine to modern technology

Wang M, Zhang L, Huang W, Huang J, Luo Y, Huang N.

Complement Ther Med. 2025 Oct;93:103222. doi: 10.1016/j.ctim.2025.103222. Epub 2025 Jul 30.

A manifesto for Alzheimer's disease drug discovery in the era of disease-modifying therapies

Hering H, Bussiere T, Liu CC, Glajch KE, Weihofen A, Grogan J, Walsh DM.

Mol Neurodegener. 2025 Aug 6;20(1):88. doi: 10.1186/s13024-025-00872-7.

Histone Deacetylase 2 in Alzheimer's Disease: A Comprehensive Molecular Blueprint for Therapeutic Targeting

Asadi K, K R, Satarker S, Gurram PC.

Mol Neurobiol. 2025 Dec;62(12):16489-16511. doi: 10.1007/s12035-025-05264-y. Epub 2025 Aug 8.

Resveratrol as a Therapeutic Agent in Alzheimer's Disease: Evidence from Clinical Studies

Puranik N, Kumari M, Tiwari S, Dhakal T, Song M.

Nutrients. 2025 Aug 5;17(15):2557. doi: 10.3390/nu17152557.

[Donanemab, an Amyloid β-targeting Antibody for Early Symptomatic Alzheimer's Disease: Summary of Clinical Study Results]

Sato S, Iwata A, Ishii K, Kamiki E, Nishimoto T.

Brain Nerve. 2025 Aug;77(8):907-920. doi: 10.11477/mf.188160960770080907.

[The mechanism of PI3K/AKT pathway in Alzheimer's disease and the research progress of acupuncture intervention]

Chen YZ, Wei YT, Xiao M, Xie WT, Yan XK.

Zhen Ci Yan Jiu. 2025 Aug 25;50(8):965-973. doi: 10.13702/j.1000-0607.20240371.

Bioenergetic failure and oxidative stress: mitochondrial contributions to Alzheimer's disease

Wasim R.

Inflammopharmacology. 2025 Sep;33(9):5273-5289. doi: 10.1007/s10787-025-01916-6. Epub 2025 Aug 27.

Nanoparticles as an Encouraging Therapeutic Approach to Alzheimer's Disease

Koga-Batko J, Antosz-Popiołek K, Nowakowska H, Błażejewska M, Kowalik EM, Beszłej JA, Leszek J.

Int J Mol Sci. 2025 Aug 10;26(16):7725. doi: 10.3390/ijms26167725.

The Therapeutic Potential of Flavonols in Alzheimer's Disease: Inhibiting Amyloid-β, Oxidative Stress, and Neuroinflammation

Zamanian MY, Khachatryan LG, Heidari M, Darabi R, Golmohammadi M, Al-Aouadi RFA, Akkol EK.

Biofactors. 2025 Sep-Oct;51(5):e70047. doi: 10.1002/biof.70047.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias